Although concurrent administration of both CAR products did not increase the effectiveness of cancer-target anti-mesothelin CAR-T cells, neither did preconditioning the tumor microenvironment (TME) with FR-specific CAR-T cells [145]. Here, MSLN is linked to neoplasm.